Hong-Yan Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hong-Yan Cai has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Zhao-Jun Wang
Key Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of Education, Taiyuan, China; Key Laboratory of Cellular Physiology, Taiyuan, China; Department of Physiology, Shanxi Medical University, Taiyuan, China
4 shared publications - Mei-Na Wu
Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan 030001, China; Department of Physiology, School of Basic Medical Sciences, Shanxi Medical University, Taiyuan 030001, China
3 shared publications - Christian Hölscher
Second Hospital, Neurology Department, Shanxi Medical University, Taiyuan, PR China
2 shared publications Bo Chen
Sinopharm North Hospital, Baotou, China
1 shared publicationChun Wang
Department of Physiology, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, 030001, China
1 shared publicationChunyan Li
Shanxi Province Veterans Psychiatric Hospital, Taigu, China
1 shared publication
Latest Publications
- Open Access
- 9 October 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1) , 770
The role of plasma oxytocin in early-onset schizophrenia: implications for disease severity and early intervention
- 9 October 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1) , 770
Open AccessThe role of plasma oxytocin in early-onset schizophrenia: implications for disease severity and early intervention
- 6 June 2024
- Published by Elsevier in Brain Research
- Vol. 1840, 149060
Mitochondrial calcium uniporter knockdown in hippocampal neurons alleviates anxious and depressive behavior in the 3XTG Alzheimer’s disease mouse model
- 6 June 2024
- Published by Elsevier in Brain Research
- Vol. 1840, 149060
Mitochondrial calcium uniporter knockdown in hippocampal neurons alleviates anxious and depressive behavior in the 3XTG Alzheimer’s disease mouse model
- 12 October 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (1) , 129-146
Intermittent fasting and Alzheimer's disease—Targeting ketone bodies as a potential strategy for brain energy rescue
Alzheimer's disease (AD) lacks effective clinical treatments. As the disease progresses, the cerebral glucose hypometabolism that appears in the preclinical phase of AD gradually worsens, leading to increasingly severe brain energy disorders. This review analyzes the brain energy deficit in AD and its etiology, brain energy rescue strategies based on ketone intervention, the effects and mechanisms of IF, the differences in efficacy between IF and ketogenic diet and the duality of IF. The evidence suggests that brain energy deficits lead to the development and progression of AD pathology. IF, which improves brain energy impairments by promoting ketone metabolism, thus has good therapeutic potential for AD.
- 12 October 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (1) , 129-146
Intermittent fasting and Alzheimer's disease—Targeting ketone bodies as a potential strategy for brain energy rescue
Alzheimer's disease (AD) lacks effective clinical treatments. As the disease progresses, the cerebral glucose hypometabolism that appears in the preclinical phase of AD gradually worsens, leading to increasingly severe brain energy disorders. This review analyzes the brain energy deficit in AD and its etiology, brain energy rescue strategies based on ketone intervention, the effects and mechanisms of IF, the differences in efficacy between IF and ketogenic diet and the duality of IF. The evidence suggests that brain energy deficits lead to the development and progression of AD pathology. IF, which improves brain energy impairments by promoting ketone metabolism, thus has good therapeutic potential for AD.
- 25 October 2022
- Vol. 74 (5) , 715-725
[Mitochondrial calcium uniporter knockdown in hippocampal neurons improved the learning and memory dysfunction of Alzheimer's disease mice].
Alzheimer's disease (AD) is a neurodegenerative disorder, which seriously affects health of the elderly, and is still irreversible up to now. Recent studies have indicated that mitochondrial dysfunction is a direct reason to promote the development of AD. Mitochondrial calcium uniporter (MCU), located in the inner membrane of mitochondria, is a key channel of mitochondrial Ca2+ uptake. Abnormal MCU expression results in imbalance of mitochondrial calcium homeostasis, ultimately leading to mitochondrial dysfunction. The purpose of this study was to determine the effects of MCU knockdown on AD hippocampal neurons and learning and memory function of AD model mice. Lentivirus and adeno-associated virus were used as vectors to transfect shRNA into hippocampal neurons (HT22 cells) and hippocampi of amyloid precursor protein (APP)/presenilin 1 (PS1)/tau AD transgenic mice, respectively, in order to interfere with MCU expression. The cellular activity of HT22 cells was detected by MTS method, and the changes of learning and memory dysfunction in APP/PS1/tau AD transgenic mice were tested by Y maze and Morris water maze. The results showed that MCU knockdown reversed the cellular activity of HT22 cells decreased by amyloid beta protein 1-42 (Aβ1-42) or okadaic acid (OA). Knockdown of MCU in hippocampal neurons improved spontaneous alternation (spatial working memory), decreased escape latency, and increased time in target quadrant and number of platform crossing (spatial reference memory) of the APP/PS1/tau mice. This study suggests that MCU knockdown in hippocampal neurons has anti-AD effect, and it is expected to be a new strategy for prevention and treatment of AD.
- 25 October 2022
- Vol. 74 (5) , 715-725
[Mitochondrial calcium uniporter knockdown in hippocampal neurons improved the learning and memory dysfunction of Alzheimer's disease mice].
Alzheimer's disease (AD) is a neurodegenerative disorder, which seriously affects health of the elderly, and is still irreversible up to now. Recent studies have indicated that mitochondrial dysfunction is a direct reason to promote the development of AD. Mitochondrial calcium uniporter (MCU), located in the inner membrane of mitochondria, is a key channel of mitochondrial Ca2+ uptake. Abnormal MCU expression results in imbalance of mitochondrial calcium homeostasis, ultimately leading to mitochondrial dysfunction. The purpose of this study was to determine the effects of MCU knockdown on AD hippocampal neurons and learning and memory function of AD model mice. Lentivirus and adeno-associated virus were used as vectors to transfect shRNA into hippocampal neurons (HT22 cells) and hippocampi of amyloid precursor protein (APP)/presenilin 1 (PS1)/tau AD transgenic mice, respectively, in order to interfere with MCU expression. The cellular activity of HT22 cells was detected by MTS method, and the changes of learning and memory dysfunction in APP/PS1/tau AD transgenic mice were tested by Y maze and Morris water maze. The results showed that MCU knockdown reversed the cellular activity of HT22 cells decreased by amyloid beta protein 1-42 (Aβ1-42) or okadaic acid (OA). Knockdown of MCU in hippocampal neurons improved spontaneous alternation (spatial working memory), decreased escape latency, and increased time in target quadrant and number of platform crossing (spatial reference memory) of the APP/PS1/tau mice. This study suggests that MCU knockdown in hippocampal neurons has anti-AD effect, and it is expected to be a new strategy for prevention and treatment of AD.
- 1 August 2021
- Published by Elsevier in Behavioural Brain Research
- Vol. 412, 113400
Chronic sleep deprivation exacerbates cognitive and synaptic plasticity impairments in APP/PS1 transgenic mice
- 1 August 2021
- Published by Elsevier in Behavioural Brain Research
- Vol. 412, 113400
Chronic sleep deprivation exacerbates cognitive and synaptic plasticity impairments in APP/PS1 transgenic mice
- 1 January 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 495 (1) , 1034-1040
Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease
- 1 January 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 495 (1) , 1034-1040
Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease